Mark D Minden

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6745178/publications.pdf

Version: 2024-02-01

158 papers	12,383 citations	94433 37 h-index	26613 107 g-index
166 all docs	166 docs citations	166 times ranked	16903 citing authors

#	Article	IF	Citations
1	Avocadoâ€derived avocadyne is a potent inhibitor of fatty acid oxidation. Journal of Food Biochemistry, 2022, 46, e13895.	2.9	4
2	TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Advances, 2022, 6, 100-107.	5.2	12
3	Novel Mango Ginger Bioactive (2,4,6-Trihydroxy-3,5-diprenyldihydrochalcone) Inhibits Mitochondrial Metabolism in Combination with Avocatin B. ACS Omega, 2022, 7, 1682-1693.	3.5	3
4	An improved molecular inversion probe based targeted sequencing approach for low variant allele frequency. NAR Genomics and Bioinformatics, 2022, 4, lqab125.	3.2	4
5	A clinical laboratoryâ€“developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia. Blood Advances, 2022, 6, 1064-1073.	5.2	11
6	SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data. Bioinformatics, 2022, 38, 2088-2095.	4.1	4
7	Pseudo-mutant P53 is a unique phenotype of <i>DNMT3A</i>-mutated pre-leukemia. Haematologica, 2022, 107, 2548-2561.	3.5	6
8	PRMT5 regulates ATF4 transcript splicing and oxidative stress response. Redox Biology, 2022, 51, 102282.	9.0	11
9	The 17â€gene stemness score associates with relapse risk and longâ€term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. EJHaem, 2022, 3, 873-884.	1.0	2
10	A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nature Medicine, 2022, 28, 1212-1223.	30.7	104
11	Shikonin impairs mitochondrial activity to selectively target leukemia cells. Phytomedicine Plus, 2022, 2, 100300.	2.0	2
12	The genomic and biological complexity of mixed phenotype acute leukemia. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 153-166.	6.1	4
13	CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood, 2021, 137, 661-677.	1.4	103
14	CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy. Blood, 2021, 137, 2171-2181.	1.4	23
15	Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KITD816V and FLT3-ITD. Leukemia, 2021, 35, 282-285.	7.2	1
16	Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood, 2021, 138, 234-245.	1.4	74
17	Loss of expression of both miR-15/16 loci in CML transition to blast crisis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	6
18	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplantation, 2021, 56, 1908-1918.	2.4	10

#	Article	IF	Citations
19	Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia.. Journal of Clinical Oncology, 2021, 39, 7019-7019.	1.6	0
20	Very long chain fatty acid metabolism is required in acute myeloid leukemia. Blood, 2021, 137, 3518-3532.	1.4	55
21	Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. Cell Stem Cell, 2021, 28, 1851-1867.e8.	11.1	43
22	Structureâ€“activity relationship of avocadyne. Food and Function, 2021, 12, 6323-6333.	4.6	5
23	Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. Current Oncology, 2021, 28, 128-137.	2.2	1
24	Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors. Cancers, 2021, 13, 5543.	3.7	9
25	Proteomics and Phospho-Proteomics Reveal Predictive Signatures of Response and Mechanisms of Resistance to Midostaurin Plus Chemotherapy in FLT3 Mutant Positive Acute Myeloid Leukemia. Blood, 2021, 138, 3462-3462.	1.4	0
26	Single-Cell Proteogenomic Sequencing Allows Early Detection of Relapse Clone with CN-LOH at FLT3-ITD Locus from Initial Diagnosis in AML. Blood, 2021, 138, 3428-3428.	1.4	1
27	KDM6 Demethylases Integrate DNA Repair Gene Regulation: Loss of KDM6A Sensitizes AML to PARP Inhibition and Potentiates with BCL2 Blockade. Blood, 2021, 138, 25-25.	1.4	0
28	Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system. Cell Reports Medicine, 2021, 2, 100470.	6.5	3
29	Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencing. Leukemia, 2020, 34, 306-311.	7.2	14
30	NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia. Leukemia, 2020, 34, 1278-1290.	7.2	27
31	Inflammatory Biomarkers, Hematopoietic Stem Cells, and Symptoms in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy. JNCI Cancer Spectrum, 2020, 4, pkaa037.	2.9	11
32	Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1995-2000.	2.0	2
33	Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome. Human Pathology, 2020, 104, 117-126.	2.0	8
34	B cell acute lymphoblastic leukemia cells mediate RANK-RANKLâ€“dependent bone destruction. Science Translational Medicine, 2020, 12, .	12.4	17
35	Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing. Science Advances, 2020, 6, .	10.3	6
36	CD200 expression marks leukemia stem cells in human AML. Blood Advances, 2020, 4, 5402-5413.	5.2	31

#	Article	IF	Citations
37	Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12332-12340.	7.1	28
38	Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Science Translational Medicine, 2020, 12, .	12.4	117
39	The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Science Translational Medicine, 2020, 12, .	12.4	33
40	Repression of LKB1 by miR-17â^¼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment. Cell Reports Medicine, 2020, 1, 100014.	6.5	16
41	Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS. Blood, 2020, 136, 1-2.	1.4	2
42	Nicotinamide Phosphoribosyltransferase Inhibitors Induce Apoptosis of AML Stem Cells through Dysregulation of Lipid Metabolism. Blood, 2020, 136, 25-26.	1.4	1
43	An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia. Blood, 2020, 136, 26-27.	1.4	2
44	Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA. Blood, 2020, 136, 35-36.	1.4	0
45	Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML. Blood, 2020, 136, 15-16.	1.4	0
46	Elevated Expression of Mir-130a in t(8,21) AML Reinforces the Aberrant Molecular Program of AML1-ETO. Blood, 2020, 136, 41-42.	1.4	0
47	Mir-125b Regulates the Self-Renewal of Acute Myeloid Leukemia Stem Cells through PTPN18 and GSK3. Blood, 2020, 136, 16-17.	1.4	4
48	Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation. Blood, 2020, 136, 8-9.	1.4	0
49	TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Blood, 2020, 136, 4-4.	1.4	1
50	IPO11 Regulates the Nuclear Import of BZW1/2 and Is Necessary for AML Cells and Stem Cells. Blood, 2020, 136, 22-23.	1.4	0
51	CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study. Blood, 2020, 136, 6-7.	1.4	3
52	The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness. Blood, 2020, 136, 1-2.	1.4	0
53	Preclinical Characterization of Cell-Based IL12 Immunotherapy Against Murine Acute Lymphoblastic Leukemia Using Intravital Imaging. Blood, 2020, 136, 25-25.	1.4	0
54	Sphingolipid Modulation Activates Proteostasis Programs to Govern Human Hematopoietic Stem Cell Self-Renewal. Cell Stem Cell, 2019, 25, 639-653.e7.	11.1	79

#	Article	IF	Citations
55	Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell, 2019, 35, 721-737.e9.	16.8	206
56	The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids. Cell Stem Cell, 2019, 24, 621-636.e16.	11.1	32
57	Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression. Experimental Hematology, 2019, 69, 27-36.	0.4	5
58	Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance. Cancer Research, 2019, 79, 5799-5811.	0.9	24
59	A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1. Blood, 2019, 134, 3940-3940.	1.4	7
60	The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Blood, 2019, 134, 3299-3299.	1.4	0
61	HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation. Blood, 2019, 134, 1676-1676.	1.4	0
62	A novel chimeric antigen receptor containing a JAKâ€“STAT signaling domain mediates superior antitumor effects. Nature Medicine, 2018, 24, 352-359.	30.7	349
63	The utility and safety of flexible bronchoscopy in critically ill acute leukemia patients: a retrospective cohort study. Canadian Journal of Anaesthesia, 2018, 65, 272-279.	1.6	7
64	Stability of sodium bicarbonate injection 8.4% in syringes over a six-week period in refrigerated temperature. Journal of Oncology Pharmacy Practice, 2018, 24, 198-200.	0.9	2
65	Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms. Clinical Cancer Research, 2018, 24, 370-382.	7.0	57
66	Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia. Chemotherapy, 2018, 63, 225-237.	1.6	2
67	Acute promyelocytic leukemia in the intensive care unit: A retrospective analysis. Leukemia Research, 2018, 73, 41-43.	0.8	2
68	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. British Journal of Cancer, 2018, 118, 1425-1433.	6.4	72
69	CD16⁺NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. Haematologica, 2018, 103, 1720-1729.	3.5	18
70	Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 2018, 559, 400-404.	27.8	617
71	Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy. Journal of Experimental and Clinical Cancer Research, 2018, 37, 88.	8.6	33
72	A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients. Blood, 2018, 132, 2765-2765.	1.4	2

#	Article	IF	Citations
73	Microrna-130a Regulates Hematopoietic Stem Cell Self-Renewal By Repressing Chromatin Modifiers and Shaping the Accessible Chromatin Landscape. Blood, 2018, 132, 3824-3824.	1.4	2
74	Myelofibrosis Is Initiated and Sustained By Rare Multipotent Stem Cells. Blood, 2018, 132, 1790-1790.	1.4	0
75	KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia. Blood, 2017, 129, 1729-1732.	1.4	3
76	Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nature Communications, 2017, 8, 1922.	12.8	89
77	Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature, 2017, 547, 104-108.	27.8	424
78	The mitochondria target drug avocatin B synergizes with induction chemotherapeutics to induce leukemia cell death. Leukemia and Lymphoma, 2017, 58, 986-988.	1.3	21
79	Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBFâ€AML) â€“ a single center analysis. Hematological Oncology, 2017, 35, 810-813.	1.7	2
80	Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 834-841.	1.3	4
81	5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. Oncotarget, 2017, 8, 8305-8314.	1.8	6
82	Inhibiting the Mitochondrial Sulfhydryl Oxidase Alr Reduces Cox17 and Alters Mitochondrial Cristae Structure Leading to the Differentiation of AML and Stem Cells. Blood, 2017, 130, 881-881.	1.4	7
83	Outcomes and Predictors of Mortality for Patients with Acute Leukemia Admitted to the Intensive Care Unit. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	51
84	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10â€Color flow cytometry diagnosis and HyperCVAD therapy. American Journal of Hematology, 2016, 91, 283-286.	4.1	40
85	Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16074.	4.1	17
86	A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature, 2016, 540, 433-437.	27.8	617
87	A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. Investigational New Drugs, 2016, 34, 614-624.	2.6	23
88	An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers. Cancer Research, 2016, 76, 1214-1224.	0.9	16
89	miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell, 2016, 29, 214-228.	16.8	216
90	Auger electron-emitting 111 In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123 + /CD131 â˜' phenotype of leukemia stem cells. Applied Radiation and Isotopes, 2016, 110, 1-7.	1.5	13

#	Article	IF	Citations
91	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. Annals of Hematology, 2016, 95, 301-310.	1.8	26
92	Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR). Blood, 2016, 128, 1638-1638.	1.4	2
93	CD200 Is a Marker of LSC Activity in Acute Myeloid Leukemia. Blood, 2016, 128, 1705-1705.	1.4	1
94	Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR). Blood, 2016, 128, 2859-2859.	1.4	7
95	Outcomes of Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients Treated with Pediatric Multi-Agent Chemotherapy and Imatinib and the Impact of Residual Disease Monitoring on Survival. Blood, 2016, 128, 3976-3976.	1.4	7
96	Safety of using escalated doses of enoxaparin prophylaxis in adults with acute lymphoblastic leukemia receiving asparaginase-based intensification therapy.. Journal of Clinical Oncology, 2016, 34, 141-141.	1.6	1
97	Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged â‰¥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study. Blood, 2016, 128, 2818-2818.	1.4	1
98	A Novel Role for INPP4B in Haematopoiesis and Leukemia. Blood, 2016, 128, 1720-1720.	1.4	0
99	Leveraging Increased Nucleoside Kinase Activity to Selectively Deplete Mitochondrial DNA (mtDNA), Impair Oxidative Phosphorylation, and Target AML Cells. Blood, 2016, 128, 1573-1573.	1.4	0
100	INPP4B is a Biomarker of Poor Prognosis in AML Which is Associated with EVI1 Overexpression and a LSC Signature. Blood, 2016, 128, 3929-3929.	1.4	0
101	A Novel Micro RNA Signature Identifies a Patient Subset with Poor Prognosis in Core Binding Factor AML. Blood, 2016, 128, 1686-1686.	1.4	0
102	Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF). Blood, 2016, 128, 4264-4264.	1.4	0
103	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. Haematologica, 2015, 100, e351-e353.	3.5	31
104	AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood, 2015, 125, 2120-2130.	1.4	227
105	A radiolabeled antibody targeting CD123+ leukemia stem cells â€“ initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML. Leukemia Research Reports, 2015, 4, 55-59.	0.4	15
106	GLI2 inhibition abrogates human leukemia stem cell dormancy. Journal of Translational Medicine, 2015, 13, 98.	4.4	80
107	Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 864-876.	16.8	265
108	Tyrosine Phosphorylation of the Lyn Src Homology 2 (SH2) Domain Modulates Its Binding Affinity and Specificity*. Molecular and Cellular Proteomics, 2015, 14, 695-706.	3.8	31

#	Article	IF	Citations
109	Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death. Cancer Research, 2015, 75, 2478-2488.	0.9	136
110	Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 1099-1108.	4.9	38
111	Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. Journal of Geriatric Oncology, 2015, 6, 262-271.	1.0	62
112	Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B. Nature Chemical Biology, 2015, 11, 401-408.	8.0	54
113	Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine, 2014, 6, 236ra62.	12.4	30
114	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Experimental Hematology, 2014, 42, 247-251.	0.4	125
115	Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature, 2014, 506, 328-333.	27.8	1,241
116	MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+/CD131â^' epitope expressed by leukemia stem cells. Leukemia Research, 2014, 38, 1367-1373.	0.8	16
117	Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop. Cancer Research, 2014, 74, 4772-4782.	0.9	64
118	Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen. Leukemia Research, 2014, 38, 532-536.	0.8	6
119	Glucopsychosine increases cytosolic calcium to induce calpain-mediated apoptosis of acute myeloid leukemia cells. Cancer Letters, 2014, 348, 29-37.	7.2	18
120	Traumatic stress symptoms in patients with acute leukemia (AL).. Journal of Clinical Oncology, 2014, 32, 9577-9577.	1.6	0
121	Gene Expression and Mutation Analysis (GEMA) â€“Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK â€“Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells. Blood, 2014, 124, 480-480.	1.4	0
122	Targeting The Mitochondrial ClpP As a Novel Therapeutic Strategy For Acute Myeloid Leukemia. Blood, 2013, 122, 3937-3937.	1.4	0
123	Inhibitors of Stat5 protein signalling. MedChemComm, 2012, 3, 22-27.	3.4	16
124	High-Dose Cytarabine-Based Consolidation Shows Superior Results for Elderly AML Patients with Intermediate Risk Cytogenetics in First Complete Remission. Blood, 2012, 120, 3574-3574.	1.4	0
125	Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell, 2011, 20, 674-688.	16.8	546
126	Dr. Ernest McCulloch. Stem Cells and Development, 2011, 20, 747-747.	2.1	0

#	Article	IF	Citations
127	Efficacy of SAR302503, a JAK2 Inhibitor, in the Treatment of a Primary Xenograft Model of Human Acute Myeloid Leukemia,. Blood, 2011, 118, 3624-3624.	1.4	0
128	SOCS2 Expression in AML: A Context Dependent Effect?.. Blood, 2007, 110, 4152-4152.	1.4	2
129	A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 908-908.	1.4	12
130	Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis.. Blood, 2006, 108, 2007-2007.	1.4	7
131	ENMD-981693 Is an Orally-Active Kinase Inhibitor with Activity towards Human Hematologic Cancers In Vitro and In Vivo.. Blood, 2006, 108, 1377-1377.	1.4	20
132	MicroRNA Expression Profiling in Sorted AML Subpopulations: A Possible Role for miR-155/BIC in Stem Cell Maintenance and Leukemogenesis.. Blood, 2005, 106, 466-466.	1.4	3
133	Dominant and Pharmacologically Sensitized ENU Mutagenesis Screens Uncover Novel Regulators of Hematopoiesis and Model Hematopoietic Disease.. Blood, 2005, 106, 1378-1378.	1.4	0
134	Induction of Transient Cytopenia To Analyze Hematopoiesis in Mutant Mice.. Blood, 2005, 106, 3158-3158.	1.4	0
135	Autologous Gamma-Delta T (GD-T) Cells in Acute Myeloid Leukemia (AML): Potential Immune Effector Cells for Minimal Disease?.. Blood, 2004, 104, 2538-2538.	1.4	0
136	Functional Assessment of the Mitochondrial Pathway of Caspase Activation in Patients with Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 2995-2995.	1.4	0
137	Silencing of Caspase 8 Expression in Leukemia Cells and Patient Samples.. Blood, 2004, 104, 2050-2050.	1.4	0
138	BAD Induces Apoptosis in Cells Over-Expressing Bcl-2 or Bcl-xL without Loss of Mitochondrial Membrane Potential. Leukemia and Lymphoma, 2001, 42, 429-443.	1.3	15
139	Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood, 2001, 98, 3541-3553.	1.4	116
140	Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach. Blood, 1999, 93, 1308-1318.	1.4	190
141	An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma. Oncogene, 1997, 15, 2929-2937.	5.9	40
142	Detection of donor cell derived acute myelogenous leukaemia in a patient transplanted for chronic myelogenous leukaemia using fluorescence in situ hybridization. British Journal of Haematology, 1996, 93, 163-165.	2.5	31
143	p53 Mutations, c-myc and bcl-2 Rearrangements in Human Non-Hodgkin's Lymphoma Cell Lines. Leukemia and Lymphoma, 1995, 19, 165-171.	1.3	40
144	Alternate Splicing Creates Two Forms of the Human Kit Protein. Leukemia and Lymphoma, 1994, 12, 441-447.	1.3	31

#	Article	IF	Citations
145	Circulating late-stage erythrold progenitors in a patient with agnagenic myeloid metaplasia. American Journal of Hematology, 1994, 45, 194-195.	4.1	0
146	A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 1994, 367, 645-648.	27.8	4,203
147	Constitutive Production of the Interleukins IL-5 and IL-6 by the Lymphoma Cell Line OCI-Ly 17 Derived from a Patient with Malignant Lymphoma and Hypereosinophilia. Leukemia and Lymphoma, 1992, 8, 97-107.	1.3	17
148	Growth of Human Lymphoma Cells in SCID Mice. Leukemia and Lymphoma, 1992, 8, 129-136.	1.3	9
149	Cloning and expression of an inducible lymphoid-specific, protein tyrosine phosphatase (HePTPase). European Journal of Immunology, 1992, 22, 235-239.	2.9	102
150	Differential regulation of Î³ and Î´ T cell antigen receptor gene expression by phorbol esters and Ca2+ ionophores in the acute lymphocyte leukemia DND41 cell line. European Journal of Immunology, 1991, 21, 2625-2628.	2.9	4
151	Organization and orientation of a human T cell receptor Î´ chain V gene segment that suggests an inversion mechanism is utilized in its rearrangement. European Journal of Immunology, 1989, 19, 571-574.	2.9	28
152	Sequence and organization of the human T cell Î´ chain gene. European Journal of Immunology, 1988, 18, 283-287.	2.9	73
153	The human t cell receptor Î±-Î´ locus: a physical map of the variable, joining and constant region genes. European Journal of Immunology, 1988, 18, 641-644.	2.9	57
154	Structure and rearrangement of the T cell receptor J alpha locus in T cells and leukemic T cell lines. European Journal of Immunology, 1988, 18, 1033-1038.	2.9	10
155	Organization and sequences of the variable, joining and constant region genes of the human T-cell receptor Î±-chain. Nature, 1985, 316, 837-840.	27.8	212
156	Breakpoints in the human T-cell antigen receptor Î±-chain locus in two T-cell leukaemia patients with chromosomal translocations. Nature, 1985, 317, 544-546.	27.8	96
157	Rearrangements of T-cell receptor gene YT35 in human DNA from thymic leukaemia T-cell lines and functional T-cell clones. Nature, 1984, 311, 385-387.	27.8	117
158	Single cell proteogenomic sequencing identifies a relapseâ€fated AML subclone carrying FLT3 â€ITD with CNâ€LOH at chr13q. EJHaem, 0, , .	1.0	1